Background. Australian Indigenous children are the only population worldwide to receive the 7-valent pneumococcal conjugate vaccine (7vPCV) at 2, 4, and 6 months of age and the 23-valent pneumococcal polysaccharide vaccine (23vPPV) at 18 months of age. We evaluated this program's effectiveness in reducing the risk of hospitalization for acute lower respiratory tract infection (ALRI) in Northern Territory (NT) Indigenous children aged 5-23 months.
at a population level. We aimed to determine whether the program reduced the risk of ALRI requiring hospitalization among NT Indigenous children aged 5-23 months of age.
METHODS

Design overview.
This was a retrospective cohort study derived from a larger study of all NT resident Indigenous infants born from 1 April 1997 through 28 February 2005 [4] . Setting. There are ∼1500 Indigenous births per year in the NT; 195% occur in 1 of 5 public hospitals [5] . Health care across the NT is highly accessible, with remote Indigenous infants presenting to primary health centers an average of every 2 weeks in the first year of life [6] .
Study participants. Children eligible for study inclusion were identified using birth records in the hospital discharge data set and augmenting these with children identified through the NT Immunisation Register (NTIR). This was possible because all persons born in the NT or who attend any public health service are allocated a unique health record number that is used for hospitalizations and for NTIR entry. The NTIR is a population-based, comprehensive immunization register that vaccine providers report to on a regular basis. Children not born in a public hospital are added to the NTIR through compulsory registration on the NT Midwives' Collection or at the first immunization or health care encounter. This system allows linkage of vaccination status and hospitalizations over time. Mobility is predominantly limited to regions within the NT, and interstate migration is infrequent.
Exposure data. Immunization history for all children in the cohort, consisting of vaccination dates and vaccine type, was obtained from the NTIR. The quality and completeness of immunization history on the NTIR is well established, and regular audits occur [7, 8] .
Outcome data. Hospitalization data were obtained from the NT Hospital Discharge Dataset, which captures all Indigenous child hospitalizations in the 5 NT public hospitals (including children transferred interstate). The primary outcome, ALRI requiring hospitalization, was defined as any discharge diagnosis code J10-J22, inclusive, as defined in the International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM) [9] . Secondary outcomes included hospitalized pneumonia not coded as viral (unspecified pneumonia codes and excluding bronchiolitis, codes J13-16, J18) and World Health Organization (WHO)-defined radiologically confirmed pneumonia [10] . For the latter, all chest radiographs, regardless of indication, obtained within 3 days of hospital admission (to exclude nosocomial pneumonia) were assessed for WHO-defined radiological consolidation by blinded readers [10] .
Covariates. Demographic information, vaccination and hospitalization histories, and region of residence at birth (Top End/Central Australia) were available.
Statistical analysis. Vaccination timing is summarized using cumulative incidence graphs. Because most children passed through у1 vaccination states during the course of follow-up, incidence of ALRI (and other pneumonia end points) was compared, not on an individual child basis, but by allocating periods of follow-up time to categories and comparing between these categories, using standard methods of survival analysis. Thus, an individual child may, at a particular age (eg, 6 months of age), be contributing to the estimation of incidence after 2 doses of 7vPCV, and at a later age (eg, 8 months of age) be contributing to comparisons concerning exposure to 3 doses of 7vPCV. We included person-time from when each child turned 5 months of age, by which time infants should have received 2 7vPCV doses, until they turned 24 months of age, died, or reached the end-date of the study (31 March 2005) . Time prior to 5 months of age was not included, because we assumed that at least 2 7vPCV doses are required for any ALRI protection; analyzing time prior to this point was therefore not informative. Children who died during the study without a date of death recorded were censored at the last vaccination or hospital admission date. A small number of children with vaccination histories outside standard practice (7vPCV after 23vPPV, a second dose of 23vPPV) were censored at the time of the later vaccination.
Crude ALRI incidence rates were calculated separately for follow-up time with 0, 1, 2, and 3 doses of 7vPCV and 0 and 1 dose of 23vPPV, by age group (5-8, 9-12, 13-16, 17-20, and 21-24 months of age), using the number of cases and total time-at-risk after each dose within each age group. Incidence rate ratios were calculated to compare rates after each dose of 7vPCV and 23vPPV with rates for those with no doses of the respective vaccine, by age group and overall, adjusted for age by the Mantel-Haenszel method. Model-based comparisons were made using Cox proportional hazards regression models, again comparing ALRI risk after each dose of 7vPCV and 23vPPV with risk having received no doses of the vaccine. As well as adjusting for age, these models allowed adjustment for potential confounding factors that reflected the child's risk profile (eg, prior hospitalizations and region of residence). Multiple episodes for a child were accounted for using the conditional risk set method [11] , stratifying by episode number and using robust standard errors. This method accounts for the fact that a child is only at risk of a second episode once they have had a first episode and that the risk of a second episode (or subsequent episode) is different from the risk of the first episode. The Efron method [12] was used to handle tied survival time.
Results from the Cox models are presented as unadjusted hazard ratios (HRs) and HRs adjusted for the child's risk profile, using the covariates sex, region of residence, and the number of ALRI and other hospital admissions prior to 5 months of age. Additional analysis allowed for a different effect of the 23vPPV vaccine in children who had received !3 doses of 7vPCV, compared with those who received у 3 doses prior to the 23vPPV vaccination.
For all analyses, the at-risk period after each dose was defined as commencing at 14 days after vaccine administration, allowing time for an immune response to that dose. Children were also not considered to be at risk of a new episode of ALRI and/ or pneumonia until 14 days after an episode commenced. Timeat-risk and new hospitalizations during this 14-day refractory period were removed from the analysis. In further analysis of potential confounding effects, we adjusted for episodes of anemia (discharge diagnosis codes: iron-deficiency anemia/anemia-unspecified) or malnutrition (codes: mild/moderate/severe protein-energy malnutrition), excluding episodes with coexisting ALRI. We also assessed whether ALRI risk was different immediately after vaccination, compared with the longer term, by fitting a separate vaccine effect in the period within 30 days of vaccination (including the 14 days immediately following vaccination) and subsequently. This analysis used an additional time-dependent covariate to categorize time since the 23vPPV vaccination.
Finally, we assessed the potential role of bias due to differential health care utilization patterns by performing the same Cox proportional hazards analysis for incidence of acute gastroenteritis requiring hospitalization (ICD-10-AM, A00-A09), the second most common cause of hospitalization among NT Indigenous infants [1] , with no coexisting ALRI.
RESULTS
There were 5482 children included in the study (Table 2) , the timing of whose vaccinations is shown in Figure 1 . In the 8315 child-years at-risk during the study period, there were 2174 episodes of ALRI that required hospitalization in 1359 children (maximum no. of hospitalizations per child, 9), with an overall incidence rate of 261 episodes per 1000 child-years (95% confidence interval [CI], 246-278 episodes per 1000 child-years). The incidence by age-group and age-specific and overall ageadjusted incidence rate ratios by vaccination status are shown in Tables 3 and 4 .
Of the 2228 respiratory diagnoses attached to ALRI hospitalizations, the most common were pneumonia unspecified (941 diagnoses), acute bronchiolitis (899), and unspecified ALRI (380). Specified viral pneumonias accounted for 95 diagnoses (influenza, 62; respiratory syncytial virus infection, 20), and specified bacterial pneumonias accounted for 26 diagnoses (pneumococcal pneumonia, 15; Haemophilus influenzae type b infection, 6). Sixteen infants (0.3%) died during the study period; there were no respiratory diagnoses reported in association with these deaths.
The crude and adjusted HRs for ALRI were elevated after each dose of 7vPCV, compared those who had received no doses (Table 5) , with adjustment for potential confounders only slightly reducing the apparent associations and leaving estimates of ∼20% relative increase in risk after vaccination. An even more striking result was seen after receipt of 23vPPV, with an estimated 39% increased risk (95% CI, 12%-71%; ), P p .002 compared with the risk associated with no receipt of 23vPPV vaccine, adjusted for available confounders and history of 7vPCV vaccination. Further analysis suggested that this increased risk after receipt of the 23vPPV vaccine in children was predominantly seen in those who had received !3 doses of 7vPCV (adjusted HR, 1.81; 95% CI, 1.32-2.48) ( Table 5 ). When the analysis was restricted to pneumonia diagnoses only (excluding specified viral pneumonias, influenza, bronchitis, and bronchiolitis), the same pattern of results was seen (Table 5) . Moreover, a similar pattern was seen for both ALRI and pneumonia when models were adjusted for anaemia and malnutrition hospitalizations and when a 2003 influenza epidemic was removed from the analysis (data not shown). There was no interaction effect between vaccination and region of residence ( and for 7vPCV and 23vPPV, respectively; data P p .60 P p .81 not shown).
There were 259 episodes of chest radiograph-confirmed pneumonia in 221 children (maximum no. of episodes per child, 4), with an overall incidence of 31 episodes per 1000 child-years (95% CI, 27-36 episodes per 1000 child-years). Although the general pattern of results (Table 5 ) was similar to that for the less specific end points, there were insufficient cases for clear interpretation of these data.
There were 1725 episodes of gastroenteritis in 1319 children in which a coexisting diagnosis of ALRI was absent (maximum no. of episodes per child, 5), with an overall incidence rate of 207 episodes per 1000 child-years (95% CI, 196-219 episodes per 1000 child-years). In sharp contrast to the results for the pneumonia end points, there was no evidence to support an increased risk of gastroenteritis hospitalizations after any dose of either vaccine (Table 5) .
Separating the time-at-risk into !31 days and у31 days after vaccination showed a similar elevated risk of ALRI requiring hospitalization after each dose of the 7vPCV vaccine (Table 6 ). However, the increased risk of ALRI was only apparent у31 days after the 23vPPV booster (adjusted HR, 1.49; 95% CI, 1.19-1.86; ), with no evidence of increased risk im-P p .001 mediately after vaccination (adjusted hazard rate ratio, 0.72; 95% CI, 0.49-1.08;
). P p .11
DISCUSSION
This is, to our knowledge, the first study to report data on the effectiveness against respiratory disease of a pneumococcal immunization program that combines a primary schedule of 7vPCV vaccination in infancy with a 23vPPV booster vaccination in the second year of life. The study included 5482 NT Indigenous infants 5-23 months of age in a setting of excess respiratory and all-cause morbidity and universal capture of ALRI requiring hospitalization. Important limitations mean that our results should be interpreted with caution; however, the data suggest that the pneumococcal immunization program may be unexpectedly increasing the risk of ALRI requiring hospitalization among vaccinated children, especially after the booster administration of 23vPPV.
Access to medical services is an obvious potential confounder in this study; that is, children who present for vaccination may also be more likely to present when unwell with ALRI. We systematically attempted to control for and minimize this effect in a number of ways, by adjusting for the number of ALRIs and other hospital admissions that occurred prior to 5 months of age in the models and comparing ALRI risk from 17 months of age after 23vPPV vaccination in children who had received at least 2 or 3 doses of 7vPCV. Furthermore, we reproduced the entire analysis using an outcome that should be unrelated to pneumococcal vaccination status-admissions to the hospital for gastroenteritis-and found no association whatsoever between risk of hospitalization and vaccination status. None of these analyses substantially affected the prima facie evidence of increased risk of ALRI associated with vaccination. Although presentation to community clinics during the first year of life is almost universal [6] , this does not translate to either timely or complete immunization in this population [13, 14] . Opportunistic immunization among hospitalized children is poor [15] , and the ongoing management of children in need of follow-up after hospital discharge is inadequate [16] , which suggests that hospitalization does not improve immunization status. Furthermore, among hospitalized children in the NT, there was no difference over the study period in 7vPCV vaccine coverage between children with and children without comorbidities of gastroenteritis, anemia, and/or malnutrition [4] . Given these factors, we believe that it is unlikely that access to medical services and differential vaccination of sicker children remain important sources of residual confounding in our analyses.
Our findings are at odds with other, largely ecological studies NOTE. 23vPPV, 23-valent pneumococcal polysaccharide vaccine; CI, confidence interval; IR, incidence rate per 1000 child-years; IRR, incidence rate ratio compared with no doses, adjusted for multiple episodes within a child.
a Adjusted for age. b Excludes specified viral pneumonias, influenza, bronchitis, and bronchiolitis. c World Health Organization-defined end point consolidation on chest radiograph obtained within 3 days of hospital admission.
that have reported decreases in all-cause pneumonia hospitalizations of up to 39% among North American children in the 7vPCV era [17] [18] [19] . These studies had substantial differences from our study-in particular, different vaccine schedules (4 dose schedule of 7vPCV)-whereas the NT has lower serotype coverage of the 7vPCV [20] , much higher rates of respiratory disease [21] , higher carriage rates with very early onset of colonization of multiple organisms [22, 23] , and vastly different socioeconomic and environmental circumstances. The American studies did not have direct linkage to vaccination status and did not account for changes in risk over small intervals of time throughout infancy (achieved by the Cox modelling approach). Three-dose coverage was less than optimal in some US regions [24] , which suggests that reductions in disease incidence could not be attributed to vaccination alone. Although it was not a primary objective, there was no evidence for a decrease in hospitalization for pneumonia in the 7vPCV era in the Alaskan Native population observational study, which involved another setting with an unusually heavy and early burden of respiratory illness [25] . Similarly, the only statistically supported effect observed in the 11-valent pneumococcal conjugate vaccine trial conducted in the Philippines was for WHO-defined, chest radiograph-confirmed pneumonia in vaccinated infants aged 3-11 months (vaccine efficacy, 34.0%; 95% CI, 4.8%-54.3%), with no impact on other respiratory end points or among older children [26] . There were increases in respiratory events after vaccination (within 28-60 days) in the clinical trials of the 7-, 9-and 11-valent pneumococcal conjugate vaccines in the United States, The Gambia [27] , South Africa [28] , and the Philippines [26] . Ongoing monitoring of these respiratory events has been identified as an important inclusion in post-licensure adverse event surveillance [29, 30] . The potential mechanisms behind increases in respiratory events after pneumococcal conjugate vaccination and after 23vPPV vaccination in the NT are speculative, particularly when considering the clear benefit of the 7vPCV on vaccinetype invasive pneumococcal disease (IPD) in these children [31] . One explanation may be rapid replacement with nonvaccine serotypes or other respiratory pathogens that have a higher relative propensity to cause mucosal disease. Site-specific disease potential associated with carriage of pneumococcal serotypes has been reported in several studies [32] [33] [34] [35] . In our population, intense and early nasopharyngeal colonization with respiratory pathogens occurs as early as 21 days of age [22] . Cross-sectional carriage surveys from before and after the in- [36] . Rapid replacement with mucogenic agents in the NT may increase ALRI in parallel with reductions in vaccinetype IPD and carriage. It is not known why the risk might be greater among children vaccinated with the 23vPPV who have not had a full primary course of 7vPCV, although recent data from Fiji indicate that the boosting effect of 23vPPV was more pronounced in children who had received 1 dose of 7vPCV than it was in those who had received 2 or 3 doses [37] . Although IPD case numbers are too small to provide supporting evidence, a second theoretical reason for our findings is the occurrence of immune hyporesponsiveness. This phenomenon has been observed after the use of meningococcal polysaccharide vaccine [38] and in the Fiji study. Attributing our findings to hyporesponsiveness is difficult, particularly given that IPD and carriage of 7vPCV serotypes have all but been eliminated. Our study lacked information on some potentially important confounders, including household size, breast feeding (although only 45% of Indigenous children aged 6-12 months are currently breast fed [39] ), birth weight, socioeconomic status of the parents, and exposure to tobacco smoke. Although residual confounding is possible, we have attempted to account for these variables by incorporating potential (albeit nonspecific) indicators of these factors in Indigenous children, such as anemia, malnutrition, prior hospitalizations for any cause, and prior hospitalizations for ALRI.
The use of discharge diagnosis codes alone as end points may be unreliable [40] [41] [42] . Direct clinical information would provide more certainty and add valuable disease severity data. Restricting the analysis to chest radiograph-confirmed pneumonia cases in this analysis was not helpful because of small case numbers. Furthermore, this study, being a secondary analysis of previously collected data, does not include risk information beyond 2 years of age, which is an important area for further research.
It is undisputed that the NT pneumococcal immunization program reduces 7vPCV vaccine-type IPD. However, our data suggest that reevaluation of the use of the 23vPPV booster at 18 months should be a matter of priority. The long-term sequelae of ALRI in these infants, particularly those who experience repeat infection, and the high prevalence of non-cystic fibrosis bronchiectasis associated with repeat ALRI, are major public health issues [43] . Additional work to confirm our findings with prospectively collected data with validated end points and stronger control of potential confounders is required.
